These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 21308365)

  • 1. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
    Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
    Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
    Cotté FE; Fardellone P; Mercier F; Gaudin AF; Roux C
    Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
    Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
    Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
    Wang Z; Ward MM; Chan L; Bhattacharyya T
    Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to osteoporosis medications amongst Singaporean patients.
    Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
    Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
    Hadji P; Kyvernitakis I; Kann PH; Niedhart C; Hofbauer LC; Schwarz H; Kurth AA; Thomasius F; Schulte M; Intorcia M; Psachoulia E; Schmid T
    Osteoporos Int; 2016 Oct; 27(10):2967-78. PubMed ID: 27172934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
    Olsen KR; Hansen C; Abrahamsen B
    Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
    Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
    Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Hadji P; Felsenberg D; Amling M; Hofbauer LC; Kandenwein JA; Kurth A
    Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
    Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
    Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
    BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
    Ganda K; Schaffer A; Pearson S; Seibel MJ
    Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
    Rabenda V; Mertens R; Fabri V; Vanoverloop J; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    Osteoporos Int; 2008 Jun; 19(6):811-8. PubMed ID: 17999022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.
    Curtis JR; Westfall AO; Cheng H; Delzell E; Saag KG
    Osteoporos Int; 2008 Nov; 19(11):1613-20. PubMed ID: 18483689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.
    Sahota O; Narayanasamy M; Bastounis A; Paskins Z; Bishop S; Langley T; Gittoes N; Davis S; Baily A; Holmes M; Leonardi-Bee J
    Health Technol Assess; 2024 Apr; 28(21):1-169. PubMed ID: 38634483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of osteoporosis treatments in Germany.
    O'Kelly J; Bartsch R; Kossack N; Borchert J; Pignot M; Hadji P
    Arch Osteoporos; 2022 Aug; 17(1):119. PubMed ID: 36044096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates.
    van den Berg P; van Haard PMM; van der Veer E; Geusens PP; van den Bergh JP; Schweitzer DH
    Osteoporos Int; 2018 Apr; 29(4):813-824. PubMed ID: 29260291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.